Human Molecular Genetics · 2022 · 15 citations · 22 references
MedicineGeneticsOncologyCancer GeneticsImmunogeneticsMolecular OncologyCancer GenomicsEnhancer FunctionSignal Transduction In CancerAntiviral Interferon ResponsesBreast Cancer GenomicsCancer Risk AssociationEnhancer Variant EffectsGenetic Risk VariantsInnate Antitumor ImmunityMalignant Breast TumorsSingle-nucleotide Polymorphisms
Women of African ancestry have the highest mortality from triple-negative breast cancer (TNBC) of all racial groups. To understand the genomic basis of breast cancer in the populations, we previously conducted genome-wide association studies and identified single nucleotide polymorphisms (SNPs) associated with breast cancer in Black women. In this study, we investigated the functional significance of the top associated SNP rs13074711. We found the SNP served as an enhancer variant and regulated TNFSF10 (TRAIL) expression in TNBC cells, with a significant association between the SNP genotype and TNFSF10 expression in breast tumors. Mechanistically, rs13074711 modulated the binding activity of c-MYB at the motif and thereby controlled TNFSF10 expression. Interestingly, TNFSF10 expression in many cancers was consistently lower in African Americans compared with European Americans. Furthermore, TNFSF10 expression in TNBC was significantly correlated with the expression of antiviral immune genes and was regulated by type I interferons (IFNs). Accordingly, loss of TNFSF10 resulted in a profound decrease in apoptosis of TNBC cells in response to type I IFNs and poly(I:C), a synthetic analogue of double stranded virus. Lastly, in a syngeneic mouse model of breast cancer, TNFSF10-deficiency in breast tumors decreased tumor-infiltrated CD4+ and CD8+ T cell quantities. Collectively, our results suggested that TNFSF10 plays an important role in the regulation of antiviral immune responses in TNBC, and the expression is in part regulated by a genetic variant associated with breast cancer in Black women. Our results underscore the important contributions of genetic variants to immune defense mechanisms.
22
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
Peter Schmid, Sylvia Adams, Hope S. Rugo et al. · New England Journal of Medicine · 2018 · 4.4K citations · Full text
Medicine, Oncology, Pharmacology +17
Race, Breast Cancer Subtypes, and Survival in the Carolina Breast Cancer Study
Lisa A. Carey, Charles M. Perou, Chad Livasy et al. · JAMA · 2006 · 3.8K citations
Medicine, Biostatistics, Oncology +14
Identification and characterization of a new member of the TNF family that induces apoptosis
Steven R. Wiley, Ken Schooley, Pamela J. Smolak et al. · Immunity · 1995 · 2.9K citations · Full text
Bystander CD8+ T cells are abundant and phenotypically distinct in human tumour infiltrates
Yannick Simoni, Étienne Becht, Michael Fehlings et al. · Nature · 2018 · 1.4K citations
Life Sciences, Immunology, Oncology +14
An oncogenic super-enhancer formed through somatic mutation of a noncoding intergenic element
Marc R. Mansour, Brian J. Abraham, Lars Anders et al. · Science · 2014 · 818 citations · Full text